Vivoryon Therapeutics N.V. (AMS: VVY)
Netherlands
· Delayed Price · Currency is EUR 2.175
+0.075 (3.57%)
Jan 3, 2025, 5:35 PM CET
Vivoryon Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | -3.62 | -3.62 | - | 10.76 | - | - | Upgrade
|
| Cost of Revenue | -0.53 | -0.53 | - | 1.57 | - | - | Upgrade
|
| Gross Profit | -3.1 | -3.1 | - | 9.2 | - | - | Upgrade
|
| Selling, General & Admin | 7.07 | 8 | 8.91 | 4.55 | 2.81 | 3.06 | Upgrade
|
| Research & Development | 21.69 | 17.64 | 20.22 | 17.45 | 13.21 | 4.79 | Upgrade
|
| Other Operating Expenses | -0.5 | -0.5 | -0.02 | -0.01 | -0.01 | -0.06 | Upgrade
|
| Operating Expenses | 28.26 | 25.14 | 29.11 | 21.99 | 16.01 | 7.79 | Upgrade
|
| Operating Income | -31.35 | -28.24 | -29.11 | -12.8 | -16.01 | -7.79 | Upgrade
|
| Interest Expense | -0.05 | -0.06 | -0.02 | -0.02 | - | -0.03 | Upgrade
|
| Interest & Investment Income | 0.64 | 0.48 | 0.04 | 0.02 | 0.03 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | -0.2 | 0.69 | 0.75 | -0.48 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | 0.04 | 0.05 | -0.1 | -0.02 | - | Upgrade
|
| EBT Excluding Unusual Items | -30.77 | -27.98 | -28.35 | -12.15 | -16.48 | -7.82 | Upgrade
|
| Merger & Restructuring Charges | -0.6 | -0.6 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.01 | -0.08 | -0.03 | - | Upgrade
|
| Pretax Income | -31.37 | -28.58 | -28.36 | -12.22 | -16.51 | -7.82 | Upgrade
|
| Income Tax Expense | -0.19 | -0.23 | -0.2 | 0.43 | - | - | Upgrade
|
| Earnings From Continuing Operations | -31.19 | -28.34 | -28.16 | -12.66 | -16.51 | -7.82 | Upgrade
|
| Net Income | -31.19 | -28.34 | -28.16 | -12.66 | -16.51 | -7.82 | Upgrade
|
| Net Income to Common | -31.19 | -28.34 | -28.16 | -12.66 | -16.51 | -7.82 | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 22 | 20 | 20 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 25 | 22 | 20 | 20 | 13 | Upgrade
|
| Shares Change (YoY) | 3.35% | 14.64% | 10.10% | 0.12% | 59.17% | 52.90% | Upgrade
|
| EPS (Basic) | -1.23 | -1.12 | -1.28 | -0.63 | -0.83 | -0.62 | Upgrade
|
| EPS (Diluted) | -1.23 | -1.12 | -1.28 | -0.63 | -0.83 | -0.62 | Upgrade
|
| Free Cash Flow | -14.56 | -21.56 | -21.81 | -11.28 | -14.08 | -11.66 | Upgrade
|
| Free Cash Flow Per Share | -0.58 | -0.85 | -0.99 | -0.56 | -0.70 | -0.93 | Upgrade
|
| Gross Margin | - | - | - | 85.42% | - | - | Upgrade
|
| Operating Margin | - | - | - | -118.91% | - | - | Upgrade
|
| Profit Margin | - | - | - | -117.57% | - | - | Upgrade
|
| Free Cash Flow Margin | - | - | - | -104.77% | - | - | Upgrade
|
| EBITDA | -31.27 | -28.16 | -29.04 | -12.73 | -15.96 | -7.76 | Upgrade
|
| EBITDA Margin | - | - | - | -118.22% | - | - | Upgrade
|
| D&A For EBITDA | 0.09 | 0.08 | 0.07 | 0.07 | 0.05 | 0.03 | Upgrade
|
| EBIT | -31.35 | -28.24 | -29.11 | -12.8 | -16.01 | -7.79 | Upgrade
|
| EBIT Margin | - | - | - | -118.91% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.